throbber
To:
`
`Subject:
`
`Sent:
`
`Sent As:
`
`Attachments:
`
`BioElectronics Corporation (mkwhelan@verizon.net)
`
`U.S. TRADEMARK APPLICATION NO. 86222506 - ANTI-INFLAMMATORY VAC - N/A
`
`7/9/2014 4:54:57 PM
`
`ECOM119@USPTO.GOV
`
`Attachment - 1
`Attachment - 2
`Attachment - 3
`Attachment - 4
`Attachment - 5
`Attachment - 6
`Attachment - 7
`Attachment - 8
`Attachment - 9
`Attachment - 10
`Attachment - 11
`Attachment - 12
`Attachment - 13
`Attachment - 14
`Attachment - 15
`Attachment - 16
`Attachment - 17
`Attachment - 18
`Attachment - 19
`Attachment - 20
`Attachment - 21
`Attachment - 22
`Attachment - 23
`Attachment - 24
`Attachment - 25
`
`UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)
`OFFICE ACTION (OFFICIAL LETTER) ABOUT APPLICANT’S TRADEMARK APPLICATION
`
`86222506
`
`*86222506*
`
`CLICK HERE TO RESPOND TO THIS LETTER:
`http://www.uspto.gov/trademarks/teas/response_forms.jsp
`
`(cid:160) (cid:160)(cid:160)(cid:160) U.S. APPLICATION SERIAL NO.(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160) (cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160)(cid:160)(cid:160) MARK: ANTI-INFLAMMATORY VAC
`(cid:160)(cid:160) (cid:160)(cid:160) (cid:160)
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160) APPLICANT: BioElectronics Corporation
`(cid:160) (cid:160)(cid:160)(cid:160)(cid:160)(cid:160) CORRESPONDENT’S REFERENCE/DOCKET
`(cid:160)(cid:160)(cid:160)
`NO:(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160)(cid:160) CORRESPONDENT E-MAIL ADDRESS:(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`
`(cid:160)(cid:160)(cid:160) CORRESPONDENT ADDRESS:
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160) BIOELECTRONICS CORPORATION
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160) BIOELECTRONICS CORPORATION
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160)(cid:160)(cid:160) 4539 METROPOLITAN CT
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160)(cid:160)(cid:160) FREDERICK, MD 21704-9452
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`
`(cid:160) (cid:160) N/A
`
`(cid:160) (cid:160) mkwhelan@verizon.net
`
`

`

`OFFICE ACTION
`
`STRICT DEADLINE TO RESPOND TO THIS LETTER
`TO AVOID ABANDONMENT OF APPLICANT’S TRADEMARK APPLICATION, THE USPTO MUST RECEIVE APPLICANT’S
`COMPLETE RESPONSE TO THIS LETTER WITHIN 6 MONTHS OF THE ISSUE/MAILING DATE BELOW.
`
`(cid:160)I
`
`SSUE/MAILING DATE: 7/9/2014
`
`The referenced application has been reviewed by the assigned trademark examining attorney.(cid:160) Applicant must respond timely and completely to
`the issue(s) below.(cid:160) 15 U.S.C. §1062(b); 37 C.F.R. §§2.62(a), 2.65(a); TMEP §§711, 718.03.
`
`(cid:160)(cid:160)
`
`TEAS PLUS APPLICANTS – TO MAINTAIN REDUCED FEE, ADDITIONAL REQUIREMENTS MUST BE MET, INCLUDING
`SUBMITTING DOCUMENTS ONLINE:(cid:160) Applicants who filed their application online using the lower-fee TEAS Plus application form must
`(1) continue to submit certain documents online using TEAS, including responses to Office actions (see TMEP §819.02(b) for a complete list of
`these documents); (2) accept correspondence from the USPTO via e-mail throughout the examination process; and (3) maintain a valid e-mail
`address.(cid:160) See 37 C.F.R. §2.23(a)(1), (a)(2); TMEP §§819, 819.02(a).(cid:160) TEAS Plus applicants who do not meet these three requirements must
`submit an additional fee of $50 per international class of goods and/or services.(cid:160) 37 C.F.R. §2.6(a)(1)(iv); TMEP §819.04.(cid:160) However, in certain
`
`situations, authorizing an examiner’s amendment by telephone will not incur this additional fee. (cid:160)(cid:160)(cid:160)
`
`SUMMARY OF ISSUES that applicant must address:
`
`SECTION 2(d) REFUSAL – LIKELIHOOD OF CONFUSION
`DISCLAIMER REQUIRED
`IDENTIFICATION OF GOODS – AMEND TO AVOID DECEPTIVENESS
`
`SECTION 2(d) REFUSAL – LIKELIHOOD OF CONFUSION
`
`Registration of the applied-for mark ANTI-INFLAMMATORY VAC is refused because of a likelihood of confusion with the mark V.A.C. in
`U.S. Registration No. 1982349.(cid:160) Trademark Act Section 2(d), 15 U.S.C. §1052(d); see TMEP §§1207.01 et seq.(cid:160) See the enclosed registration.
`
`(cid:160)T
`
`rademark Act Section 2(d) bars registration of an applied-for mark that so resembles a registered mark that it is likely a potential consumer
`would be confused, mistaken, or deceived as to the source of the goods and/or services of the applicant and registrant.(cid:160) See 15 U.S.C. §1052(d).(cid:160)
`A determination of likelihood of confusion under Section 2(d) is made on a case-by case basis and the factors set forth in In re E. I. du Pont de
`Nemours & Co., 476 F.2d 1357, 177 USPQ 563 (C.C.P.A. 1973) aid in this determination.(cid:160) Citigroup Inc. v. Capital City Bank Grp., Inc., 637
`F.3d 1344, 1349, 98 USPQ2d 1253, 1256 (Fed. Cir. 2011) (citing On-Line Careline, Inc. v. Am. Online, Inc., 229 F.3d 1080, 1085, 56 USPQ2d
`1471, 1474 (Fed. Cir. 2000)).(cid:160) Not all the du Pont factors, however, are necessarily relevant or of equal weight, and any one of the factors may
`control in a given case, depending upon the evidence of record.(cid:160) Citigroup Inc. v. Capital City Bank Grp., Inc., 637 F.3d at 1355, 98 USPQ2d at
`1260; In re Majestic Distilling Co., 315 F.3d 1311, 1315, 65 USPQ2d 1201, 1204 (Fed. Cir. 2003); see In re E. I. du Pont de Nemours & Co., 476
`F.2d at 1361-62, 177 USPQ at 567.
`
`(cid:160)I
`
`n this case, the following factors are the most relevant:(cid:160) similarity of the marks, similarity and nature of the goods, and similarity of the trade
`channels of the goods.(cid:160) See In re Viterra Inc., 671 F.3d 1358, 1361-62, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012); In re Dakin’s Miniatures Inc. ,
`59 USPQ2d 1593, 1595-96 (TTAB 1999); TMEP §§1207.01 et seq.
`
`(cid:160)T
`
`he overriding concern is not only to prevent buyer confusion as to the source of the goods and/or services, but to protect the registrant from
`adverse commercial impact due to use of a similar mark by a newcomer.(cid:160) See In re Shell Oil Co., 992 F.2d 1204, 1208, 26 USPQ2d 1687, 1690
`(Fed. Cir. 1993).(cid:160) Therefore, any doubt regarding a likelihood of confusion determination is resolved in favor of the registrant.(cid:160) TMEP
`§1207.01(d)(i); see Hewlett-Packard Co. v. Packard Press, Inc., 281 F.3d 1261, 1265, 62 USPQ2d 1001, 1003 (Fed. Cir. 2002); In re Hyper
`Shoppes (Ohio), Inc., 837 F.2d 463, 464-65, 6 USPQ2d 1025, 1026 (Fed. Cir. 1988).
`
`COMPARISON OF MARKS(cid:160)
`The applicant’s mark is ANTI-INFLAMMATORY VAC.
`
`(cid:160)T
`
`he registered mark is V.A.C.
`
`(cid:160)
`(cid:160)(cid:160)(cid:160)
`(cid:160)
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160)
`(cid:160)
`

`

`The registered mark and the “VAC” portion of the applied-for mark are essentially phonetic equivalents and thus sound similar. (cid:160) Similarity in
`sound alone may be sufficient to support a finding that the marks are confusingly similar.(cid:160) In re White Swan Ltd., 8 USPQ2d 1534, 1535 (TTAB
`1988); see In re 1st USA Realty Prof’ls, Inc. , 84 USPQ2d 1581, 1586 (TTAB 2007); TMEP §1207.01(b)(iv).
`
`Although marks are compared in their entireties, one feature of a mark may be more significant or dominant in creating a commercial
`impression.(cid:160) See In re Viterra Inc., 671 F.3d 1358, 1362, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012); In re Nat’l Data Corp. , 753 F.2d 1056,
`1058, 224 USPQ 749, 751 (Fed. Cir. 1985); TMEP §1207.01(b)(viii), (c)(ii).(cid:160) Matter that is descriptive of or generic for an applicant’s goods
`and/or services is typically less significant or less dominant in relation to other wording in a mark.(cid:160) See In re Chatam Int’l Inc. , 380 F.3d 1340,
`1342-43, 71 USPQ2d 1944, 1946 (Fed. Cir. 2004); In re Binion, 93 USPQ2d 1531, 1534 (TTAB 2009).
`
`(cid:160)I
`
`n the present case, the attached evidence shows that the wording “ ANTI-INFLAMMATORY” in the applied-for mark is merely descriptive of
`or generic for applicant’s goods that are used to reduce inflammation. (cid:160) Thus, this wording is less significant in terms of affecting the mark’s
`commercial impression, and renders the wording “VAC” the more dominant element of the mark.
`
`(cid:160)A
`
`dding a term to a registered mark generally does not obviate the similarity between the compared marks, as in the present case, nor does it
`overcome a likelihood of confusion under Section 2(d).(cid:160) See Coca-Cola Bottling Co. v. Jos. E. Seagram & Sons, Inc., 526 F.2d 556, 557, 188
`USPQ 105, 106 (C.C.P.A. 1975) (finding BENGAL and BENGAL LANCER and design confusingly similar); In re Toshiba Med. Sys. Corp., 91
`USPQ2d 1266, 1269 (TTAB 2009) (finding TITAN and VANTAGE TITAN confusingly similar); In re El Torito Rests., Inc., 9 USPQ2d 2002,
`2004 (TTAB 1988) (finding MACHO and MACHO COMBOS confusingly similar); TMEP §1207.01(b)(iii).(cid:160) In the present case, the VAC and
`V.A.C.(cid:160) portions of the marks are nearly identical.(cid:160) Therefore the addition of the descriptive wording “ANTI-INFLAMMATORY” does not
`obviate the similarity of the marks.
`
`(cid:160)I
`
`n these respects, the literal portions of the applicant’s mark and that of the registrant are highly similar in appearance, sound, connotation and
`commercial impression, and therefore, are likely to cause confusion as to the origin of the goods.
`
`(cid:160)C
`
`OMPARISON OF GOODS
`The applicant’s goods are identified as “Low frequency electromagnetic therapy apparatus” (cid:160) The goods named in the registration
`comprise/include “medical devices, namely pump units for promoting wound healing, receptacles for collecting wound drainage, and parts and
`
`accessories for the foregoing.” (cid:160)(cid:160)
`
`The goods and/or services of the parties need not be identical or even competitive to find a likelihood of confusion.(cid:160) See On-line Careline Inc. v.
`Am. Online Inc., 229 F.3d 1080, 1086, 56 USPQ2d 1471, 1475 (Fed. Cir. 2000); Recot, Inc. v. Becton, 214 F.3d 1322, 1329, 54 USPQ2d 1894,
`1898 (Fed. Cir. 2000) (“[E]ven if the goods in question are different from, and thus not related to, one another in kind, the same goods can be
`
`related in the mind of the consuming public as to the origin of the goods.”); TMEP §1207.01(a)(i). (cid:160)(cid:160)
`
`The respective goods and/or services need only be “related in some manner and/or if the circumstances surrounding their marketing [be] such
`that they could give rise to the mistaken belief that [the goods and/or services] emanate from the same source.” (cid:160) Coach Servs., Inc. v. Triumph
`Learning LLC, 668 F.3d 1356, 1369, 101 USPQ2d 1713, 1722 (Fed. Cir. 2012) (quoting 7-Eleven Inc. v. Wechsler, 83 USPQ2d 1715, 1724
`(TTAB 2007)); Gen. Mills Inc. v. Fage Dairy Processing Indus. SA, 100 USPQ2d 1584, 1597 (TTAB 2011); TMEP §1207.01(a)(i). (cid:160)(cid:160) In this case,
`it is enough that applicant’s goods and registrant’s goods are both used to promote healing.
`
`(cid:160)T
`
`he attached Internet evidence consists of excerpts about therapy devices for use in the field of wound healing.(cid:160) This evidence establishes that
`the applicant’s goods and registrant’s goods are similar or complementary in terms of purpose or function.
`(cid:160) Therefore, applicant’s and
`registrant’s goods and/or services are considered related for likelihood of confusion purposes. (cid:160) See, e.g., In re Davey Prods. Pty Ltd., 92 USPQ2d
`1198, 1202-04 (TTAB 2009); In re Toshiba Med. Sys. Corp., 91 USPQ2d 1266, 1268-69, 1271-72 (TTAB 2009).
`
`(cid:160)E
`
`vidence obtained from the Internet may be used to support a determination under Trademark Act Section 2(d) that goods and/or services are
`related.(cid:160) See, e.g., In re G.B.I. Tile & Stone, Inc., 92 USPQ2d 1366, 1371 (TTAB 2009); In re Paper Doll Promotions, Inc., 84 USPQ2d 1660,
`1668 (TTAB 2007).
`
`(cid:160)T
`
`he marks are used to identify medical devices for use in the field of healing.(cid:160) The same consumers will be exposed to the therapeutic products
`identified with the marks.(cid:160) The similarities among the marks and the goods of the parties are so great as to create a likelihood of confusion.
`
`CONCLUSION
`Accordingly, in view of the closely related nature of the goods of the parties and the strong similarity of the marks and their commercial
`impressions, confusion as to the source of the goods is likely under Section 2(d) of the Trademark Act.
`
`(cid:160)A
`
`lthough the examining attorney has refused registration, the applicant may respond to the refusal to register by submitting evidence and
`arguments in support of registration.(cid:160) If the applicant chooses to respond to the refusal to register, the applicant must also respond to the
`
`(cid:160)(cid:160)
`(cid:160)(cid:160)
`

`

`following.
`
`DISCLAIMER REQUIRED
`Applicant must disclaim the wording “ ANTI-INFLAMMATORY” because it merely describes an ingredient, quality, characteristic, function,
`feature, purpose, or use of applicant’s goods and/or services, and thus is an unregistrable component of the mark. (cid:160) See 15 U.S.C. §§1052(e)(1),
`1056(a); DuoProSS Meditech Corp. v. Inviro Med. Devices, Ltd., 695 F.3d 1247, 1251, 103 USPQ2d 1753, 1755 (Fed. Cir. 2012) (quoting In re
`
`Oppedahl & Larson LLP, 373 F.3d 1171, 1173, 71 USPQ2d 1370, 1371 (Fed. Cir. 2004)); TMEP §§1213, 1213.03(a).(cid:160)(cid:160)
`
`The attached evidence from online dictionaries shows this wording means “ used to reduce inflammation” and “counteracting or suppressing
`inflammation.” Therefore, the wording merely describes applicant’s therapeutic devices that reduce inflammation.
`
`(cid:160)A
`
`n applicant may not claim exclusive rights to terms that others may need to use to describe their goods and/or services in the marketplace.(cid:160) See
`Dena Corp. v. Belvedere Int’l, Inc. , 950 F.2d 1555, 1560, 21 USPQ2d 1047, 1051 (Fed. Cir. 1991); In re Aug. Storck KG, 218 USPQ 823, 825
`(TTAB 1983).(cid:160) A disclaimer of unregistrable matter does not affect the appearance of the mark; that is, a disclaimer does not physically remove
`the disclaimed matter from the mark.(cid:160) See Schwarzkopf v. John H. Breck, Inc., 340 F.2d 978, 978, 144 USPQ 433, 433 (C.C.P.A. 1965); TMEP
`
`§1213.(cid:160)(cid:160)
`
`If applicant does not provide the required disclaimer, the USPTO may refuse to register the entire mark.(cid:160) See In re Stereotaxis Inc., 429 F.3d
`1039, 1040-41, 77 USPQ2d 1087, 1088-89 (Fed. Cir. 2005); TMEP §1213.01(b).
`
`(cid:160)A
`
`pplicant should submit a disclaimer in the following standardized format:
`
`No claim is made to the exclusive right to use “ANTI-INFLAMMATORY” apart from the mark as shown.
`
`(cid:160)F
`
`or an overview of disclaimers and instructions on how to satisfy this disclaimer requirement online using the Trademark Electronic Application
`System (TEAS) form, please go to http://www.uspto.gov/trademarks/law/disclaimer.jsp.
`
`IDENTIFICATION OF GOODS – AMEND TO AVOID DECEPTIVENESS
`The use or intended use of the applied-for mark on goods that do not in fact have or exhibit anti-inflammatory properties is or will be deceptive.(cid:160)
`See TMEP §1203.02-.02(b).(cid:160) To avoid a deceptiveness refusal, applicant must amend the identification to indicate that the goods possess this
`relevant feature or characteristic.(cid:160) See TMEP §§1203.02(e)(ii), (f)(i), 1402.05 et seq.(cid:160) Merely amending the identification to exclude goods or
`services with the named feature or characteristic will not avoid a deceptiveness refusal.(cid:160) TMEP §1203.02(f)(i).
`
`(cid:160)T
`
`herefore, applicant must amend the identification to the following, if accurate:(cid:160)(cid:160)
`
`Class 10: Low frequency electromagnetic therapy apparatus for reducing or suppressing inflammation
`
`(cid:160)A
`
`n applicant may only amend an identification to clarify or limit the goods and/or services, but not to add to or broaden the scope of the goods
`and/or services.(cid:160) 37 C.F.R. §2.71(a); see TMEP §§1402.06 et seq., 1402.07.
`
`RESPONSE GUIDELINES(cid:160)
`To expedite prosecution of the application, applicant is encouraged to file its response to this Office action online via the Trademark Electronic
`Application System (TEAS), which is available at http://www.uspto.gov/trademarks/teas/index.jsp.(cid:160) If applicant has technical questions about the
`TEAS response to Office action form, applicant can review the electronic filing tips available online at
`http://www.uspto.gov/trademarks/teas/e_filing_tips.jsp and email technical questions to TEAS@uspto.gov.
`
`(cid:160)I
`
`f applicant has questions regarding this Office action, please telephone or e-mail the assigned trademark examining attorney.(cid:160) All relevant e-
`mail communications will be placed in the official application record; however, an e-mail communication will not be accepted as a response to
`this Office action and will not extend the deadline for filing a proper response.(cid:160) See 37 C.F.R. §2.191; TMEP §§304.01-.02, 709.04-.05.(cid:160) Further,
`although the trademark examining attorney may provide additional explanation pertaining to the refusal(s) and/or requirement(s) in this Office
`action, the trademark examining attorney may not provide legal advice or statements about applicant’s rights. (cid:160) See TMEP §§705.02, 709.06.
`
`(cid:160)(cid:160)
`(cid:160)
`(cid:160)(cid:160)
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`

`

`/John M. C. Kelly/
`United States Patent and Trademark Office
`Trademark Examining Attorney
`Law Office 119
`571-272-9412
`john.kelly@uspto.gov
`
`(cid:160)(cid:160)(cid:160)
`
`TO RESPOND TO THIS LETTER: (cid:160) Go to http://www.uspto.gov/trademarks/teas/response_forms.jsp. (cid:160) Please wait 48-72 hours from the
`issue/mailing date before using the Trademark Electronic Application System (TEAS), to allow for necessary system updates of the application.(cid:160)
`For technical assistance with online forms, e-mail TEAS@uspto.gov.(cid:160) For questions about the Office action itself, please contact the assigned
`trademark examining attorney.(cid:160) E-mail communications will not be accepted as responses to Office actions; therefore, do not respond to
`this Office action by e-mail.
`
`(cid:160)A
`
`ll informal e-mail communications relevant to this application will be placed in the official application record.
`
`(cid:160)W
`
`HO MUST SIGN THE RESPONSE:(cid:160) It must be personally signed by an individual applicant or someone with legal authority to bind an
`applicant (i.e., a corporate officer, a general partner, all joint applicants).(cid:160) If an applicant is represented by an attorney, the attorney must sign the
`
`response.(cid:160)(cid:160)
`PERIODICALLY CHECK THE STATUS OF THE APPLICATION: (cid:160) To ensure that applicant does not miss crucial deadlines or official
`notices, check the status of the application every three to four months using the Trademark Status and Document Retrieval (TSDR) system at
`http://tsdr.uspto.gov/. (cid:160) Please keep a copy of the TSDR status screen. (cid:160) If the status shows no change for more than six months, contact the
`Trademark Assistance Center by e-mail at TrademarkAssistanceCenter@uspto.gov or call 1-800-786-9199. (cid:160) For more information on checking
`status, see http://www.uspto.gov/trademarks/process/status/.
`
`(cid:160)T
`
`O UPDATE CORRESPONDENCE/E-MAIL ADDRESS:(cid:160) Use the TEAS form at http://www.uspto.gov/trademarks/teas/correspondence.jsp.
`
`(cid:160)(cid:160)
`

`

`mun //mEdIEa\—dH:|\EIrIar
`
`thefreeduzllunar cum/amunflammalur
`
`DE/19/2EI14 12 33 D5 PM
`
`2 ammammmw
`[—infIam’eboré]
`
`Elymulngy: Gk‘ arm i L, fnflammara, In sel afire
`1 Dana
`g In a substance or procedure max counlemnls or re:uses mnainmauon
`2 an armlnflzmmalory dmg
`Mwws Mama! uimnew. aw. edmIm.E1flW.E\s:vI=r.
`
`Page
`' 0" III
`ewoiu arawsei
`
`i|=.xT I IE3P‘fi'L¥I'—J
` —- F Th2FreeDicIinnzry f‘ Gougle F Bing
`Em"
`HIEWEEDICHDNARY rm Seaucll
`"““"""“
`35' @
`l_RanunDe<Me new
`1,
`F‘ Ward/Arllcle F startswiu: “ Ends wllh ‘‘ Text
`6 559,939 524 vismmsaewea
`ewe
`
`I Dictionary: Jlnesaums
`
`I Encyciopenia I wixipenu:encvcwllenia
`_ ll ___
`
`
`
`ant nflammatory Aismimain:uicuonammesaums_vimmma
`
`Pllgelouls
`I :T
`—Ad D G
`
`
`CVIE / Hnk E3
`Share 1 Bar
`in
`E Son
`E3 PMS’ mend
`S Y 0°95
`D
`"Jig/ ii“
`“"“Y "‘*‘°“E"1 °€"‘--
`amiinflammatoty fan 1i in-flam-ma-Iu ryl [—ln—€|am'ah4DV"e)v:nuEI|e1aEI\rIg or suppvessing inflammaliun; also, an agent Ihal 5» acts
`M umvmm mm
`DDl‘IViSMEd\El‘D\IIK\wl1filYfDfH(lMhCun§|lmEf§ em: I?! Sanndgrs, an imwirll D1 E\§:wai Wm AH rights rsenad.
`Prev-iemn-run Tue-mam
`furA\IPi|1erlls rm om
`Mme TEI‘h‘1\
`
`
`
`Feedback
`iii».
`
`
`
`
`
`V‘
`’ E3
`
`‘DR
`Share
`
`flgfigféku ”"' 3‘
`, »,
`,
`
`.,
`
`P
`
`
`
`
`
`
`1. cuumerztlmg ur supplessing innmwumuu
`mm antiinllammaiory [an"|e—in—nam’aMar—e]
`Samsung
`2. an agent mail so acts
`Gafaxy S“4
`|lH|Ev—K£:naEnnynlnpaflm and mmmm Madmna Nursing nmlAmen Hash): smnm Eaman,a2nu:| u,s...mm_ Ill vmprmlnl Elsamnr, mu NIIWME rzewufl
`Active‘ ' wAIcH LIVE JUNE an s 29 ‘‘
`AT :3: DDPIVI E'I' D8591
`........;
`amiinllammatory,
`‘
`adj/n serves Ia reheve infiammatiau in cases, such as injury or infeclron; beneficial trail ofsome e55en!i2\ DHS
`/lav/eI\\savv.:nl(Eafl Danna’? Manse Ian: Knnwl
`Jana: Mushy‘; uiam»,Iflflnmiflemgulavymi MlanntmeMeduwe in ms, Elsaaer
`My hunkinaiiis
`Piease M at regisiem use Immiams You
`can also lug M with Faceimok, Gnagle, Twiller,
`
`
`4 .9,
`an-Qj-in-[lam-ma-ta-ry (3
`Reducing infiamlnalion by acnng an body respunses, wimoumiiecuy amagonzing me causative agent denouiig agenls such as glucoconiculds and aspirin.
`nm em. Mam! Du£mnavy§Far\u zm:
`
`
`
`
`an-1.i-in-llam-ma-to-ry (ar|'
`in—fia
`mg)
`Reducing inflaminaiinn y ac ng on
`y respnnsas‘ winimudiiecciy antagonizing lhe causative agent denmiiig agenls such as glumcnflicnlds and aspirin
`Ma1uz\DIx1mrIarvfnl lha mam PIMLEVWIE sun Nursmu e Fanex zmz
`
`“__n
`
`
`

`

`mun //madlflairdllziltlrlar
`
`See Mler delulis
`sliup Now
`‘"0’
`‘‘’‘’‘”5’
`
`,__,

`
` Aiivsnlsemem laud banner?
`Please lel usmaw;
`
`lnelreeuieliunar earn/anliinflarninalur
`Ella/la/2El14 12 33 D5 PM
`wieinau iaimmiynrime rieam Prurgeunaariu lmrslifl e Faflex zuiz
`
`an-Ii-in-flam-ma-to-ry (aniein4iam'a—riire)
`Reducing irillaininaliimriy
`iespunses, wnnnu:direeny anlagonizing me nausanve agenr; derlonrlg agents such as glllcnmnicnlfls and aspii-in
`
`Mailmi u.a......aa.u.. am »...m...;er..i 1iI12
`
`Patient discussion about amiinfiammatory.
`I1. Can anyone sllggesl a ireaurienuur plantar fast us, Ipzrtlmln Illlrasnund, pllysin, aniunlianirnaiory agenls? My lrienii has has Piamar Fasciilisformnre irian 1 year and has pelsevemd wilh all lhe ususal lrealmenls
`above plus leis ol res: imrn welght-bunny and eleuzrliull
`A. Padded fool spllnls. silicone lieels insen and special shoes (e g. arch-suppofllng shoes] may also nelp. rl-iese are usually sold and med by a pralessianal. Eiercise is another lmpclrlam measure. Some paiienis zienem iroln
`avu ing walking lxarellxrl er in sleepers mi rauier using slrues fninl inefirsi s1ep
`Mare advanced Inedlnlellln iricluile :|2ruil]-Iulzel arreeilreiiue iineeilinre, bu|u|illulu IllXilI(L4Y!1i|dI Iu IJu|ux) IlIjuI:|iulI: and slulyely.
`The prognosis is usually favorable, and mast iianams achieve ieliei iifrlie pain.
`However. all uiuie above isJust zar general knowledge — ifyou nave ally speeini: quesnun, you may warn in lmnsull a uaclor
`veu may mad rue-re nere
`wwwrllm nihglwvlmedlhep|u5len:ylaIIit}el[|D7fl21 lrlin
`Read more or ask a guesliari aboul aniiinuammzlagg
`rneamrerriisrumaes uyuuieuixmsmqgamimmrmerneogmmummmemmemuuurimmmmim uremaemmieuymeae nnlflmlms
`
`Wan] lnuianlr TFD far im eJrisIellt9’I Tell a friend auairl us. add a Ink lnuiis page ur \/Ell me webmasters gage ror free fun conlerll.
`link In iliis page:
`<3 hZ:f='httDl//lIled1¢:al—

`dx:t1:lna:y.theExeed1ztinnnty.can/nnti1nE)nlmnnta:y'>nnt1
`1nf]anlmaCnIy(/B)
`
`Please hmikmark wml sucial rn
`
`
`
`yaurvmes are noticed and appreclaledi
`
`Ii.-carve
`
`i
`
`MyrbeLriq is a prescripllan medicine
`{or adults used to (reel overscrive
`bladder (GAB) with symptoms o[
`urgency, frequency, and leakage.
`
`¥iIyri:e|m}' innraaegreni my muse wsurblurm
`Dr:-sswt-mlrlcra
`euvmihsynuvhl-andDrussurs
`\\':VSE ir mu have .1 nisiary at man uiuaa pressure ii
`is rt-ninrrlmeriiit-d mar laur iizlzlar mm Ilwur hklnfl
`Drrsswe willie yau an-Iaivlng Mirhelrlil Mrrueiria
`
`/4dvclLl3cnIcn|(Bnfl rmnnerv mam lctu: lmuw)
`
` FeedyuIlr brain feed a riungg Child
`
`— Mentioned in
`
`
`
`— References in periodicals archive
`renenliy ieeaned me resulls or a pnpuIallan—based_ c:§e4:Dmm| study regarding nskfaniars for pedlamr:
`invasive group A slrepluccunal (GAS) irrieciioli (1 1, noung mat ille 'new" use urnansieraiilal uniimlarnmamiy
`
`— Medical browser
`
`
`
`— Full browser
`. milluluul
`e ai..i..uu,
`. nnfllflvvlllrln fl1Ih'lflIWlHflH\!
`
`

`

`mun //m2dIcaLdn:hnnar
`
`thefreeduzlltmar cum/amunflammalur
`
`DE/19/2EI1412 33 D5 PM
`
`—|flfEn
`ivumyiamxgconicasiemne
`aremelacm
`
`Atela
`ghen
`aremsahcyllc acid
`AHFEHDCDNIEOSIBIIXUS
`Akehia gumala
`an wnflzmmalo 1
`an rflflalnlnam 1 3 enls
`aim-rnflammam 1 dlug
`Amklnflammalng thug:
`amimnammarag agents
`amimnammareg drug
`amilnllammatey Ieukalriene
`Amwheumatic Drugs
`Ascnplin
`asplnn
`
`drugs (Nsmns), defined a; nsmn use Q week; befme diagnosis, was assocmen wim Ilwaslve (ms infection,
`whems sell-defined "regular NSAID usewa5 not
`Nonstemidar anfllnflammalflydmgg and gmugfii snegromaaa/ , by Mulla Zuber E /Emegfng Fnfectious
`Diseases
`Instead, dlug tumpznies hzu/9 tnntenttmed on 2-,:pivv\, ihupmren, cyzlmnxyganzsig inhibitors, and ulnar
`anliinflammatnry dings man blcmka single biochemical palhllay but don't plnlecl EH5
`Running mterielence fresh aggmach to fighting lnflammallon by Segga N /Science News
`More results »
`
`l1>
`
` anlllmmlme
`anlllnfechall wlamlll
`anlllnfeclwe
`amllrrfccfivl: dmg
`> allliinfiummllory
`anllmllammala [2 ents
`anliinflammalau drug
`anliinflammalau leukouiene
`anlllnluhllat cuagutsnl complex
`anlnnitnatm
`anlllnsulln
`armkenutman
`anllkelugenesls
`anllkelugenir:
`Antikickbzck Lzw
`
`
`AdChn£ma
`
`o annnmmge auluanfibudy
`I zrmlmmune
`an Mac an vivamln
`anhlnfechve
`
`0 anhlnfechve drug
`.A.. nfinmalulm No Ealnmwden
`> almlllllammamry
`o armmllammam agent
`a armmllammam agent
`I antiinflammai agenl
`0 zntiinflammai agenl
`o anmnflammagy agenl
`o znnnnflammam agents
`0 zrmlnflalllmafi drug
`I annlnllalllluafl drug
`a armmnammam drug
`. anninnammam harmanen
`
`<
`
`\/
`
`H Set sail In your
`Snrvllung -6: xy 5 4
`laundry room.
`‘G I.TE Cl Flinn: .
`
`> :v|x(k.(:I:]l on
`8499"“
`* win: new2-yur enmm
`
`
`
`um Aaguflw
`Mwemsementtfiud mnnerr Please we:us mm
`
`_ «’-' Tl|eFreeDinion|ry 4‘ Goagle
`\,/(2%
`""vREE N“[ seam.
`5‘ Wmvd]Ar|i:|e -" smriswini F Ends mm ‘‘ Texl
`
`W
`Furs:-fag:Free1oulnnr1.2:na1muug|wmumIneDgy|Bzsubaunnkifi
`Free T°°'5
`rnn.a....m.. Fin:-imfia1II|.1nhm\ I|lL7ubIa¢Ick|malc\|g 0%‘.
`MtleSIe|Ta1lux1lke|P1iw3c[g:[\Faeflbsck|Aavu\\§ewihUs|(2np;ryItI2n14F.IE1( mi
`uigmiiiu
`an Wm... m|flIrs|vdIfl3av(lud\r1Qd'>mnl1i'Yr$§i|IvIfi4 Via-arum gazgraphu. and mu mtuenizaaa isiw
`wamanmau-w§unn.1I.is.immaii...si..Janmmmss:a5my1muu»=amandsm
`imaiaadiu be mi ‘in vbanfa ias'vm..suum,o. am .4 i|=+;i|i mam, w anv wawgssmax.
`
`

`

`mun //www nxfurddlctwunavxes cum/us/definumu/amerman 2nI1\IsH/anmnflammatuv
`EIE/19/201412 3419 PM
`
`l°"9"°9°'"°”°“
`. OxfordDIchonarIes
`
`Dlcunnary
`
`FRENCH
`
`GERMAN
`
`ITALIAN
`
` Type a word 0!’ phrase
`
`ENGUSH
`E-ynon_vn15
`
`SPANISH
`Grammal
`
`EN
`
`\U.‘S\
`
`Definificu uf 11Im'—x'nfi'ammamry m English:
`
`anti-inflammatory
`Syllabificatiun: an-n—in-flaxn-ma-wry
`Pronun:1atmn: /,ancéin‘aama,tiu—é, ,anfi—
`/
`
`ADJEC'I1VE
`
`(Chiefly Df a dmg) used to reduce inflammation,
`MORE EXAMPLE SENTENCES
`
`Fmriautn re
`
`NOLIM [plural anti"-inflalznnalnries)
`
`An an!i—>nflamma1ory drug.
`MORE EXAMPLE SENTENCES
`
`Back :0 mp
`
`~
`
`MORE ONA.NT|—|'NFLAI‘IMATOR‘{
`
`Nearby W0rds
`
`€
`

`

`mun //www uxfurddictiunaiies cum/us/defimiinn/amerman Bnuiish/anii—inflamma|ui
`EIE/19/201412 3419 PM
`
`MUM: tXAMPLi: S|:Ni l:Nl.'tS
`
`\t
`
`More definitions ofanti-inflammatory
`
`Definition of anti-inflammatory in:
`- The British & World English dictionary
`
`anIi—g
`antmnfeciive
`anfi-inflammatory
`
`a””"”‘e"ed“5‘
`Anti-Lebanon Mountains
`
`More words in this
`category
`
`ampneiamine
`antichulinergic
`anxiolvtic
`arsphenamine
`bactericide
`
`Translate ami-
`inflammatory
`
`ink) Italian
`
`‘
`‘M: or THE DA!’
`
`
`

`

`mm:/mwuxfurdmmnnanas cum/u idafinrfiuvv/smsrman enrfllsh/anh—mflEmma4urV'
`DE/1522011112 SW19 PM
`
`F'mnunr.\at|Dn, fmuzé
`
`ADJECTNE
`
`scruffy and n g\ecIed m anpearante
`
`
`
`

`

`Print: Jul 9, 2D14
`
`T4-E76320
`
`TYPED DRAWING
`
`Serial Number
`T46T632O
`
`Status
`REGISTERED AND RENEWED
`
`Word Mark
`v.A.c.
`
`Standard Character Merit
`No
`
`Registration Number
`;9e2349
`
`Date Registered
`;99sxOsx25
`
`Type of Marin
`TRADEMARK
`
`Register
`DR:NcIDAL
`
`Mark Drawing Code
`[1
`TYPED DRAWING
`
`Owner
`KO: LICENSING,
`TEXAS T82492248
`
`INO. OORRORATION DELAWARE 12930 IH—IO West San Antonio
`
`Goodsfservioes
`Class Status —— ACTIVE.
`
`IC 010.
`
`Us
`
`U26 U39 044.
`
`G 6: 3: medical
`
`devices, namely pump units for promoting wound healing, receptacles
`for collecting wound drainage, and parts and accessories for the
`foregoing. First Use:
`l995HU4fUl. First Use In Commerce:
`l995fU4fUl.
`
`Filing Date
`l995fU5fGl
`
`Examining Attorney
`WARD.
`JOYCE A.
`
`Attorney of Record
`Pamela B. Hu”
`
`

`

`Pfini:JuI9,2D14
`
`75874141
`
`DESIGN MARK
`
`Serial Number
`T58T4l4l
`
`Status
`REGISTERED AND RENEWED
`
`Word Mark
`NAODDN ASSISTED OLOSDRE
`
`Standard Character Merit
`No
`
`Registration Number
`2557555
`
`Date Registered
`2OO2x12x1O
`
`Type Of Marl:
`TRADEMARK
`
`Register
`DR:NcIDAL
`
`Mark Drawing Code
`[1
`TYPED DRAWING
`
`Owner
`Kc: Licensing, Inc. OORSORATION DELAWARE 12930 IH—IO West San Antonio
`TEXAS T82492248
`
`Goodsfserviees
`[ medical
`G & S:
`U26 U39 044.
`US
`IC 010.
`Class Status -- ACTIVE.
`devices, namely, pump units for promoting Wound healing, receptacles
`for collecting wound drainage, and parts and accessories for the
`foregoing ]
`* parts and accessories for pump units for promoting Wound
`healing and receptacles for collecting wound drainage*. First Use:
`l995/Odfifll. First Use In Commerce:
`l995fO4fOl.
`
`Disclaimer Statement
`NO OLAIN IS MADE TO THE EXCLUSIVE RIGHT TO USE "VAODDN ASSISTED" ASART
`FROM THE MRRK AS SHOWN.
`
`Filing Date
`l999Hl2Hl5
`
`Examining Attorney
`SNARE, TINA L.
`
`

`

`Print: Jul 9, 2D14
`
`T587-II-141
`
`Attorney of Record
`Pamela B. Huff
`
`

`

`

`

`mun //www ream/er Ix I:u/I2!rmcaHessarch/chrurrrowuundsf
`
`EI7/EIBJQIJM DA 33 59 PM
`
`RECOVER
`
`
`Clinimlly Prawn Median! Therapy far MeHim! Pmfessinrmlx
`
`carom
`
`Iacnnanogy
`
`Apmlmalxnns
`
`cumml Research
`
`uq
`
`Pronucns
`
`In me man:
`
`Dlslrilmlurs
`
`amvacn
`
`Chronic Wounds
`
`RecoveryRx® Chronic Wound Studies
`
`Introduction
`Low—Leve| Pulsea Rauzolreouency Frerds and ms Treatment of solflossue rnrunes
`The arm nnms remure Is In mmrne me mam nrrysmrngrcar nrncesses mvnlwen rmrre nealrrrg mwnurrns armm suggest a mechanism my wnrcn nursen
`ramuvreuuerrw (RF) er-reruvr unrre currents rrrauuea In ussues Mme aunrrcalrurr urmaterrergy. mawrrlruerrce ns Cuurse
`Emnrrasrs Is grven to me can maven my enema rrr rrmmrung ma Drncesses mwounn nearrng Relerence rs mane m the gmwrng evruenne mat nursed RFenargy
`sums me trme cuurse ulwuurru rrearrrrg and me nyumnesrs Is urunuseamat one nussrme mecrremsm uy wrrrcrr nursen RF energy accererates wound rrealrrrg rs
`by remmng enema
`
`Purseu ramurrerzuerrcy eremrurrragrretr: new
`merapy rs zvarrams m varrnus rurms Extarrsrve
`crrnrcar research has been conducted wrm a
`
`BioEIactronlcs Medlcal Device Chronlc Wound Recuvary
`nueeeare Fnol Ulcer Fallen!
`
`View(lomplele punnsnea Paper
`
`

`

`mun //www ream/er 7:4 cu/errnneewesearerrterrrunrewuunusfl
`
`mw
`
`'
`
`
`
`EI7/EIBJQIZH4 DA 33 59 PM
`Umma: researcu was ueerr uuuuuueuWm H
`rarge numner er cumica: pumrcanons rm rrardIn
`heal and mronrc wounds Mass researm
`however‘ has been dune mm dewces mat use
`relanvelymgtl power‘ are rarge and cums
`based Trrese Lrrerapres have been srrmwrr tn
`be evfectrve rmtdue some iveuuenny emre
`enmrmmrrs (ummme dauyvman mrnlnrrae
`nmued prxemrar nu wulesplead use
`ReczweryR>@Iecmlology rs are mlmaxunzamun
`am-recmaruunar lame emuumemusedm
`h06DI|a!5 and cumcs Amarrces rn rrucmelemorrrcs have made rl possrme to dehvei me c11n|:a|\y amen and 511nevmr emended durauon trrerarmn smaH
`covrvemem andcos|—e1fe<.'uve apwcauons
`Recrwerykmcs anmled tumewomld. Incovouratmgmlo me dressmgor on low onrre dressing fx>r241u:ws per day The radmnerxuency emuromagneuc field wom
`Recoverymoa passes mmugh me dvessrng, Ineveible, me device dues nolneedto ne m mrea conlaamnm me snrr, ms makes for aswnpre apprrmnran unnrs
`Dowerful Ieohnologyr whrar rm: oniy Drolnotes wound heafing but also reduces mmmc wmmd Dain
`Vuumrumrusesuufiesmichinnlmen-fieutsuimunmssiashumensuiuxeticnloersmmuloerslrmnvymemnuanurermaaun
`Published Case Series
`m a case senes anew pauerns we were treatedwrm Reccweryamau Temple rum and Anne CJmIc‘Pm1aIlel|)n1a‘aiH7!e pauenls rradmng standing mcels mau
`rradvaned preumus meqapres rrre slutty penodwas srx ween: T

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Try refreshing this document from the court, or go back to the docket to see other documents.

We are unable to display this document.

Go back to the docket to see more.